Medifast

Q2 FY2026 EarningsQ2 FY26 performance beat consensus estimates on both top and bottom lines: revenue was $76.4M vs. $72.7M expected, and diluted EPS loss of $0.28 was significantly narrower than the $0.65 consensus loss. Despite a 27.6% YoY revenue decline due to a 48.7% drop in active earning coaches, productivity per coach rose 41% YoY. Management's Q3 revenue guidance of $60M-$80M encompasses the $72.7M consensus, while the outlook for a return to profitability in Q4 FY26 indicates a potential inflection point in the business turnaround.